Taken together, the results of our study and previous reports suggest that PUM1-TRAF3 inhibits TRAF3 by competitively binding TRAF2 and NIK, thereby inducing the relative inactivation of TRAF3 and resulting in CCA proliferation via the non-canonical NF-kB pathway. Here, TRAF2 is linked to cholangiocarcinoma.